Adam Singer, MD

In this closing segment on advanced renal cell carcinoma, Dr. Ornstein synthesizes key themes from the case discussion, emphasizing how disease biology and clinical presentation guide second-line treatment decisions. He highlights that patients with early progression after frontline therapy represent a higher-risk group that often requires a more aggressive treatment approach.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein introduces a patient with high disease burden who progresses within 8 months of frontline immunotherapy plus VEGF receptor targeted therapy, highlighting a more aggressive disease course. He emphasizes that early progression and limited depth of response raise concern for more refractory disease biology.

In this forward-looking segment on advanced renal cell carcinoma, Dr. Ornstein asks the panel to consider how treatment decisions may evolve if newer combination therapies become available in the second-line setting. He introduces the potential role of lenvatinib combined with belzutifan and asks how this regimen might fit into clinical practice.

In this segment on advanced renal cell carcinoma, Dr. Ornstein asks how clinicians differentiate among VEGF receptor targeted therapies when selecting treatment for patients with slower disease progression after prior immunotherapy. He highlights the perception that different TKIs may vary in both efficacy and toxicity.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient with intermediate-risk disease who experienced progression after 14 months of frontline dual immune checkpoint inhibitor therapy. He highlights the importance of interpreting prior treatment response and clinical status when selecting second-line therapy.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient who progresses after frontline immunotherapy plus VEGF receptor targeted therapy, with prior tolerability challenges including hand-foot syndrome and diarrhea. He highlights the expanding range of second-line options, including HIF-2α inhibitors.

In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a clinical scenario of a patient with disease progression after frontline dual immune checkpoint inhibitor therapy, emphasizing the need to individualize second-line treatment decisions in the absence of certain emerging approvals.

In this segment on advanced renal cell carcinoma, Dr. Ornstein explores real-world transition rates from first-line to subsequent lines of therapy, asking how often patients reach second- and third-line treatment in clinical practice.

In this segment on advanced renal cell carcinoma, Dr. Ornstein transitions the discussion to the second-line setting, noting that most patients will eventually experience disease progression and require additional therapy. He highlights that treatment goals evolve in the refractory setting, where achieving disease control becomes the primary objective rather than long-term durable remission.

In this segment on advanced renal cell carcinoma, Dr. Ornstein emphasizes that treatment is only effective if patients are able to remain on therapy, framing dose management as a critical component of clinical care. He asks how clinicians approach dosing and tolerability, particularly with VEGF receptor targeted therapy–based combinations.

In this segment on advanced renal cell carcinoma, Dr. Ornstein raises the important issue of real-world treatment attrition, noting that not all patients are able to receive subsequent lines of therapy after disease progression. He frames this as a key consideration when selecting first-line treatment.

In this segment on advanced renal cell carcinoma, Dr. Ornstein shifts the discussion to the role of treatment sequencing when selecting first-line therapy. He raises the question of how anticipated second-line options may influence initial treatment decisions in the context of multiple effective frontline regimens.

In this segment on advanced renal cell carcinoma, Dr. Ornstein guides the discussion toward differentiating available frontline treatment options, focusing on the choice between dual immune checkpoint inhibitor therapy and combinations of immunotherapy with VEGF receptor targeted therapies.

In this opening segment on advanced renal cell carcinoma, Ornstein introduces the evolving frontline treatment landscape, highlighting the expanded role of immune checkpoint inhibitor–based combinations and VEGF receptor–targeted therapies.